Fleury S.A. - Asset Resilience Ratio
Fleury S.A. (FLRY3) has an Asset Resilience Ratio of 13.87% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Fleury S.A. (FLRY3) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Fleury S.A.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Fleury S.A..
Liquid Assets Composition Over Time
This chart breaks down Fleury S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore FLRY3 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$0.00 | 0% |
| Short-term Investments | R$1.88 Billion | 13.87% |
| Total Liquid Assets | R$1.88 Billion | 13.87% |
Asset Resilience Insights
- Moderate Liquidity: Fleury S.A. has 13.87% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Fleury S.A. Industry Peers by Asset Resilience Ratio
Compare Fleury S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468 |
Diagnostics & Research | 15.34% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for Fleury S.A. (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Fleury S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 16.19% | R$2.14 Billion ≈ $420.03 Million |
R$13.22 Billion ≈ $2.59 Billion |
-1.57pp |
| 2024-12-31 | 17.76% | R$2.32 Billion ≈ $455.22 Million |
R$13.06 Billion ≈ $2.56 Billion |
+9.97pp |
| 2023-12-31 | 7.79% | R$902.21 Million ≈ $177.03 Million |
R$11.58 Billion ≈ $2.27 Billion |
-8.79pp |
| 2022-12-31 | 16.58% | R$1.29 Billion ≈ $253.56 Million |
R$7.79 Billion ≈ $1.53 Billion |
+3.92pp |
| 2021-12-31 | 12.67% | R$769.39 Million ≈ $150.97 Million |
R$6.07 Billion ≈ $1.19 Billion |
-5.78pp |
| 2020-12-31 | 18.45% | R$1.02 Billion ≈ $199.61 Million |
R$5.51 Billion ≈ $1.08 Billion |
+2.83pp |
| 2019-12-31 | 15.62% | R$795.89 Million ≈ $156.17 Million |
R$5.10 Billion ≈ $1.00 Billion |
-4.96pp |
| 2018-12-31 | 20.57% | R$804.49 Million ≈ $157.85 Million |
R$3.91 Billion ≈ $767.30 Million |
+1.56pp |
| 2017-12-31 | 19.01% | R$670.57 Million ≈ $131.58 Million |
R$3.53 Billion ≈ $692.13 Million |
+5.59pp |
| 2016-12-31 | 13.42% | R$403.47 Million ≈ $79.17 Million |
R$3.01 Billion ≈ $589.80 Million |
+13.28pp |
| 2015-12-31 | 0.15% | R$4.70 Million ≈ $922.81K |
R$3.20 Billion ≈ $628.73 Million |
+1.13pp |
| 2014-12-31 | -0.98% | R$-31.46 Million ≈ $-6.17 Million |
R$3.21 Billion ≈ $629.81 Million |
-0.58pp |
| 2013-12-31 | -0.40% | R$-12.97 Million ≈ $-2.54 Million |
R$3.21 Billion ≈ $630.09 Million |
-0.01pp |
| 2012-12-31 | -0.40% | R$-10.86 Million ≈ $-2.13 Million |
R$2.74 Billion ≈ $537.28 Million |
-0.41pp |
| 2011-12-31 | 0.02% | R$434.00K ≈ $85.16K |
R$2.83 Billion ≈ $555.63 Million |
+0.01pp |
| 2010-12-31 | 0.00% | R$19.00K ≈ $3.73K |
R$1.33 Billion ≈ $260.61 Million |
+1.36pp |
| 2009-12-31 | -1.36% | R$-17.07 Million ≈ $-3.35 Million |
R$1.26 Billion ≈ $246.48 Million |
+2.93pp |
| 2008-12-31 | -4.29% | R$-26.44 Million ≈ $-5.19 Million |
R$616.76 Million ≈ $121.02 Million |
-2.36pp |
| 2007-12-31 | -1.93% | R$-9.75 Million ≈ $-1.91 Million |
R$505.94 Million ≈ $99.27 Million |
+5.58pp |
| 2006-12-31 | -7.51% | R$-24.48 Million ≈ $-4.80 Million |
R$326.11 Million ≈ $63.99 Million |
-- |
About Fleury S.A.
Fleury S.A., together with its subsidiaries, engages in the provision of diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. The company also provides medical services in the areas of diagnostics, laboratory support, infusions, clinical analyses, health management, healthcare, assistance medi… Read more